Abstract
Interleukin 23 (IL-23) is integral to the pathogenesis of chronic inflammation. The resolution of acute inflammation is an active process mediated by specific signals and mediators such as resolvin E1 (RvE1). Here we provide evidence that RvE1, in nanogram quantities, promoted the resolution of inflammatory airway responses in part by directly suppressing the production of IL-23 and IL-6 in the lung. Also contributing to the pro-resolution effects of RvE1 treatment were higher concentrations of interferon-γ in the lungs of RvE1-treated mice. Our findings indicate a pivotal function for IL-23 and IL-6, which promote the survival and differentiation of IL-17-producing T helper cells, in maintaining inflammation and also identify an RvE1-initiated resolution program for allergic airway responses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Holgate, S.T. The epidemic of allergy and asthma. Nature 402, B2–B4 (1999).
Martinez Molina, D. et al. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 448, 613–616 (2007).
Busse, W.W. & Lemanske, R.F., Jr. Asthma. N. Engl. J. Med. 344, 350–362 (2001).
Schwartz, J. & Weiss, S.T. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I). Eur. Respir. J. 7, 1821–1824 (1994).
Serhan, C.N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197–1204 (2000).
Serhan, C.N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025–1037 (2002).
Gilroy, D.W., Lawrence, T., Perretti, M. & Rossi, A.G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3, 401–416 (2004).
Serhan, C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101–137 (2007).
Campbell, E.L. et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 21, 3162–3170 (2007).
Schwab, J.M., Chiang, N., Arita, M. & Serhan, C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447, 869–874 (2007).
Bettelli, E., Oukka, M. & Kuchroo, V.K. TH-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 (2007).
Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).
Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
Langowski, J.L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461–465 (2006).
Chan, J.R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577–2587 (2006).
Molet, S. et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 108, 430–438 (2001).
Nakae, S. et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375–387 (2002).
Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005).
Chen, Y. et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J. Biol. Chem. 278, 17036–17043 (2003).
Schnyder-Candrian, S. et al. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203, 2715–2725 (2006).
Pichavant, M. et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J. Exp. Med. 205, 385–393 (2008).
Cheung, P.F., Wong, C.K. & Lam, C.W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J. Immunol. 180, 5625–5635 (2008).
Yang, X.O. et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063–1075 (2008).
Levy, B.D. et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4 . Nat. Med. 8, 1018–1023 (2002).
Bannenberg, G.L. et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345–4355 (2005).
Zhou, L. et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8, 967–974 (2007).
Stumhofer, J.S. et al. Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937–945 (2006).
Yoshimoto, T., Yoshimoto, T., Yasuda, K., Mizuguchi, J. & Nakanishi, K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 179, 4415–4423 (2007).
Batten, M. et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7, 929–936 (2006).
Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).
Sheibanie, A.F., Tadmori, I., Jing, H., Vassiliou, E. & Ganea, D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 18, 1318–1320 (2004).
Muhlbauer, M., Chilton, P.M., Mitchell, T.C. & Jobin, C. Impaired Bcl3 up-regulation leads to enhanced LPS-induced IL-23p19 gene expression in IL-10−/− mice. J. Biol. Chem. 283, 14182–14189 (2008).
Bonnans, C. et al. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed. Pharmacother. 61, 261–267 (2007).
Yago, T. et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9, R96 (2007).
Jovanovic, D.V. et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160, 3513–3521 (1998).
Arita, M. et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102, 7671–7676 (2005).
Hudert, C.A. et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 103, 11276–11281 (2006).
Ivanov, S. et al. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am. J. Respir. Cell Mol. Biol. 36, 442–451 (2007).
Barczyk, A., Pierzchala, W. & Sozanska, E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97, 726–733 (2003).
Doganci, A. et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 115, 313–325 (2005).
De Rose, V. et al. IFN-γ inhibits the proliferation of allergen-activated T lymphocytes from atopic, asthmatic patients by inducing Fas/FasL-mediated apoptosis. J. Leukoc. Biol. 76, 423–432 (2004).
Tong, J. et al. Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. J. Exp. Med. 203, 1173–1184 (2006).
Yoshida, M. et al. Effect of interferon-gamma on allergic airway responses in interferon-γ-deficient mice. Am. J. Respir. Crit. Care Med. 166, 451–456 (2002).
Arita, M. et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713–722 (2005).
Cash, J.L. et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205, 767–775 (2008).
Serhan, C.N. et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2, 325–332 (2007).
Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L.E. & Levy, B.D. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174, 5033–5039 (2005).
Levy, B.D. et al. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172, 824–830 (2005).
Levy, B.D. et al. Protectin D1 Is generated in asthma and dampens airway Inflammation and hyperresponsiveness. J. Immunol. 178, 496–502 (2007).
Arita, M. et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912–3917 (2007).
Levy, B.D. et al. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J. 13, 903–911 (1999).
Acknowledgements
We thank G.L. Zhu, B. Ith and K. Gotlinger for technical assistance. Supported by the US National Institutes of Health (AI068084 to B.D.L. and P50-DE016191 to B.D.L. and C.N.S.).
Author information
Authors and Affiliations
Contributions
O.H. did experiments and analyzed data, was involved in experimental design and wrote the manuscript; M.C. provided reagents, analyzed data and was involved in experimental design; R.Y. provided reagents; C.N.S. provided reagents, analyzed data, was involved in experimental design and helped write the manuscript; and B.D.L conceived the project, did and designed experiments, analyzed data and helped write the manuscript.
Corresponding author
Ethics declarations
Competing interests
B.D.L. and C.N.S. are inventors on patents assigned to Brigham and Women's Hospital on the resolvins and their analogs that are licensed for clinical development and are the subject of consulting agreements.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 (PDF 76 kb)
Rights and permissions
About this article
Cite this article
Haworth, O., Cernadas, M., Yang, R. et al. Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 9, 873–879 (2008). https://doi.org/10.1038/ni.1627
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.1627
This article is cited by
-
Pro- and anti-inflammatory bioactive lipids imbalance contributes to the pathobiology of autoimmune diseases
European Journal of Clinical Nutrition (2023)
-
Dietary long-chain omega 3 fatty acids modify sphingolipid metabolism to facilitate airway hyperreactivity
Scientific Reports (2022)
-
Maresin 1 protects the liver against ischemia/reperfusion injury via the ALXR/Akt signaling pathway
Molecular Medicine (2021)
-
Molecular biochemical aspects of salt (sodium chloride) in inflammation and immune response with reference to hypertension and type 2 diabetes mellitus
Lipids in Health and Disease (2021)
-
Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy
Nature Communications (2021)